Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), a ten-amino-acid peptide the hypothalamus normally releases in short pulses to tell the pituitary gland to produce luteinizing hormone (LH) and follicle-stimulating hormone (FSH) — the two hormones that, in turn, drive testosterone production in men and ovulation in women. It has a genuine FDA approval history, which puts it in a different category than most peptides discussed on this site, but that history is more complicated than a simple "approved" label suggests.
A Real, If Discontinued, FDA Approval
Gonadorelin was approved by the FDA under two brand names. Factrel was approved as a single-dose diagnostic injection used to test whether a patient's hypothalamus and pituitary gland were functioning normally. Lutrepulse was approved for a different purpose entirely: delivered continuously through a small pump in short pulses — 5 micrograms roughly every 90 minutes over 21 days — to treat infertility or absent periods (amenorrhea) caused by the hypothalamus not releasing enough natural GnRH. Both products are now discontinued in the United States. That doesn't mean gonadorelin disappeared; it means the branded, FDA-inspected manufacturing lines shut down, and most current access runs through compounding pharmacies making their own versions under a physician's prescription, which is a meaningfully different regulatory situation than a drug with an active, FDA-monitored approval.
Pulsatile Versus Continuous Is the Entire Story
The single most important thing to understand about GnRH-based peptides is that how they're dosed determines whether they stimulate or shut down the reproductive hormone system — and this is a useful contrast with the site's existing guide to leuprolide. Pulsatile dosing, delivered in short bursts that mimic the body's own rhythm, keeps the pituitary responsive and stimulates LH and FSH release, which is why Lutrepulse could induce ovulation. Continuous, steady exposure does the opposite: it desensitizes the pituitary's GnRH receptors and ultimately suppresses the whole axis, which is the mechanism behind GnRH agonist drugs like leuprolide (Lupron), used to shut down hormone production in prostate cancer and endometriosis. Same starting molecule family, opposite physiological outcome, entirely dependent on dosing pattern.
Why It Shows Up in TRT Clinics Today
Outside its original diagnostic and fertility uses, gonadorelin has found a newer off-label niche: men's hormone clinics prescribing it alongside testosterone replacement therapy (TRT), on the theory that small, frequent pulsatile doses can help preserve natural testicular function and fertility that TRT alone tends to suppress — a role often filled instead by hCG (human chorionic gonadotropin). This combination use hasn't been validated in the kind of large, randomized human trials that supported gonadorelin's original diagnostic and fertility approvals decades ago; most of what's published is smaller clinical experience and physiologic reasoning about pulsatile dosing rather than dedicated outcome trials in TRT patients specifically. That's a real evidence gap worth being clear-eyed about, even for a peptide with a legitimate FDA history in other contexts.
Safety Considerations
Gonadorelin's historical approvals came with standard precautions around injection-site reactions and, for the pump-delivered version, risks tied to the infusion device itself. Because most current use is compounded and off-label, dosing schedules, purity, and sterility depend entirely on the individual pharmacy rather than on FDA-reviewed manufacturing standards. Anyone considering gonadorelin as part of a TRT or fertility plan should discuss it with an endocrinologist, urologist, or reproductive specialist who can weigh it against better-studied alternatives like hCG and explain exactly what evidence does and doesn't exist for the specific protocol being proposed.